These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36754594)

  • 1. Baricitinib for juvenile idiopathic arthritis: a monocentric case series.
    Maccora I; Oliverio T; Pagnini I; Marrani E; Mastrolia MV; Simonini G
    Ann Rheum Dis; 2023 Jul; 82(7):994-995. PubMed ID: 36754594
    [No Abstract]   [Full Text] [Related]  

  • 2. Questioning the Effectiveness of Baricitinib for Pulmonary Manifestations of Rheumatoid Arthritis.
    Chertoff J; Ataya A
    Am J Respir Crit Care Med; 2017 Nov; 196(10):1353. PubMed ID: 28358994
    [No Abstract]   [Full Text] [Related]  

  • 3. Tomographic regression of pulmonary rheumatoid nodules under baricitinib therapy.
    Venerito V; Lopalco G; Anelli MG; Cacciapaglia F; Iannone F
    Rheumatology (Oxford); 2019 Mar; 58(3):440. PubMed ID: 30212893
    [No Abstract]   [Full Text] [Related]  

  • 4. Herpes simplex infection in a patient with rheumatoid arthritis treated with baricitinib: a case report.
    Valor-Méndez L; Voskens C; Rech J; Kleyer A; Schett G
    Rheumatology (Oxford); 2021 Apr; 60(4):e122-e123. PubMed ID: 33141876
    [No Abstract]   [Full Text] [Related]  

  • 5. Baricitinib (olumiant) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2018 Jul; 60(1551):120-121. PubMed ID: 30036348
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome.
    Nousari Y; Wu BC; Valenzuela G
    Clin Exp Dermatol; 2021 Oct; 46(7):1330-1332. PubMed ID: 33914946
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytomegalovirus Enteritis in a Patient with Rheumatoid Arthritis Receiving Baricitinib.
    Sugawara E; Matsui K; Amasaki Y
    J Rheumatol; 2020 Dec; 47(12):1835-1836. PubMed ID: 33262287
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
    Taylor PC; Takeuchi T; Burmester GR; Durez P; Smolen JS; Deberdt W; Issa M; Terres JR; Bello N; Winthrop KL
    Ann Rheum Dis; 2022 Mar; 81(3):335-343. PubMed ID: 34706874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis with 3 years of treatment: results from a long-term study.
    Smolen JS; Xie L; Jia B; Taylor PC; Burmester G; Tanaka Y; Elias A; Cardoso A; Ortmann R; Walls C; Dougados M
    Rheumatology (Oxford); 2021 May; 60(5):2256-2266. PubMed ID: 33200220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.
    Keystone EC; Taylor PC; Tanaka Y; Gaich C; DeLozier AM; Dudek A; Zamora JV; Cobos JAC; Rooney T; Bono S; Arora V; Linetzky B; Weinblatt ME
    Ann Rheum Dis; 2017 Nov; 76(11):1853-1861. PubMed ID: 28798049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
    Smolen JS; Genovese MC; Takeuchi T; Hyslop DL; Macias WL; Rooney T; Chen L; Dickson CL; Riddle Camp J; Cardillo TE; Ishii T; Winthrop KL
    J Rheumatol; 2019 Jan; 46(1):7-18. PubMed ID: 30219772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib: JAK inhibition for rheumatoid arthritis.
    Gras J
    Drugs Today (Barc); 2016 Oct; 52(10):543-550. PubMed ID: 27910962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis.
    Keystone EC; Genovese MC; Schlichting DE; de la Torre I; Beattie SD; Rooney TP; Taylor PC
    J Rheumatol; 2018 Jan; 45(1):14-21. PubMed ID: 28811354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baricitinib for the treatment of rheumatoid arthritis.
    Kubo S; Nakayamada S; Tanaka Y
    Expert Rev Clin Immunol; 2016 Sep; 12(9):911-9. PubMed ID: 27427830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baricitinib: A Review in Rheumatoid Arthritis.
    Al-Salama ZT; Scott LJ
    Drugs; 2018 May; 78(7):761-772. PubMed ID: 29687421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.
    Kacar M; Fitton J; Gough AK; Buch MH; McGonagle DG; Savic S
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32669454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of Baricitinib 4 mg for the Treatment of Moderate to Severe Rheumatoid Arthritis.
    Dabal TD; Haltom MB; Patel PP; Son CK; Joglekar KP; Groeschell CM; Chumpia MM; Kamal SF; Seth A; Jackson CD
    South Med J; 2021 May; 114(5):288-292. PubMed ID: 33942113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.